Patents by Inventor Julianto Setiady

Julianto Setiady has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11396543
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: July 26, 2022
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
  • Publication number: 20220169745
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: November 10, 2021
    Publication date: June 2, 2022
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Publication number: 20200362029
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 19, 2020
    Inventors: Olga AB, Neeraj KOHLI, Thomas CHITTENDEN, Julianto SETIADY
  • Publication number: 20200325240
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 15, 2020
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Publication number: 20200270361
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 27, 2020
    Inventors: Jutta DECKERT, Julianto SETIADY, Peter U. PARK
  • Patent number: 10556958
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 11, 2020
    Assignee: Debiopharm International, S.A.
    Inventors: Jutta Deckert, Julianto Setiady, Peter U. Park
  • Patent number: 10544230
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 28, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Publication number: 20190023805
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: June 7, 2018
    Publication date: January 24, 2019
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Patent number: 10017578
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 10, 2018
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Publication number: 20170306041
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 26, 2017
    Inventors: Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
  • Patent number: 9637547
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: May 2, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Publication number: 20160340438
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Application
    Filed: August 10, 2016
    Publication date: November 24, 2016
    Inventors: Jutta DECKERT, Julianto SETIADY, Peter U. PARK
  • Patent number: 9447189
    Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 20, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Jutta Deckert, Julianto Setiady, Peter U. Park
  • Publication number: 20160060345
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: August 7, 2015
    Publication date: March 3, 2016
    Inventors: Julianto SETIADY, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Publication number: 20160017053
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: May 8, 2015
    Publication date: January 21, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Julianto SETIADY, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
  • Patent number: 9238690
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: January 19, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
  • Patent number: 9233171
    Abstract: The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: January 12, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Thomas Chittenden
  • Patent number: 9125896
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 8, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Publication number: 20150093388
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 2, 2015
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Patent number: 8790649
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: July 29, 2014
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne